Enrico Costa

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Topics

Sickle Cell Disease

Radical Prostatectomy

Sentinel Lymph Node

Top Venues

American journal of hematology

Orphanet journal of rare diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Enrico Costa, Antonella Isgrò, Mariane De Montalembert, Hubertus G Leufkens, Russell E Ware, Lucia De Franceschi
Successes and pitfalls in orphan drug development for sickle cell disease. Blood advances 8 (10) (2024)
Maria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, Frauke Naumann-Winter, Enrico Costa, Darius Matusevicius, Dinah M Duarte, Eva Malikova, Dinko Vitezić, Kristina Larsson, Armando Magrelli, Violeta Stoyanova-Beninska, Segundo Mariz
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. Gene therapy 31 (7-8) (2024)
Enrico Costa, Antonella Isgrò, Mariane De Montalembert, Hubertus G Leufkens, Russell E Ware, Lucia De Franceschi
SUCCESSES AND PITFALLS IN ORPHAN DRUG DEVELOPMENT FOR SICKLE CELL DISEASE. Blood advances (2024)
Maria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, Frauke Naumann-Winter, Enrico Costa, Darius Matusevicius, Dinah M Duarte, Eva Malikova, Dinko Vitezić, Kristina Larsson, Armando Magrelli, Violeta Stoyanova-Beninska, Segundo Mariz
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. Gene therapy 31 (7-8) (2024)
Maria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, Frauke Naumann-Winter, Enrico Costa, Darius Matusevicius, Dinah M Duarte, Eva Malikova, Dinko Vitezić, Kristina Larsson, Armando Magrelli, Violeta Stoyanova-Beninska, Segundo Mariz
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. Gene therapy (2024)
Maria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, Frauke Naumann-Winter, Enrico Costa, Darius Matusevicius, Dinah M Duarte, Eva Malikova, Dinko Vitezić, Kristina Larsson, Armando Magrelli, Violeta Stoyanova-Beninska, Segundo Mariz
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. Gene therapy (2024)
Maria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, Frauke Naumann-Winter, Enrico Costa, Darius Matusevicius, Dinah M Duarte, Eva Malikova, Dinko Vitezić, Kristina Larsson, Armando Magrelli, Violeta Stoyanova-Beninska, Segundo Mariz
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. Gene therapy (2024)
Enrico Costa, Antonella Isgrò, Mariane De Montalembert, Hubertus G Leufkens, Russell E Ware, Lucia De Franceschi
Successes and pitfalls in orphan drug development for sickle cell disease. Blood advances 8 (10) (2024)
Maria Elisabeth Kalland, Tomas Pose-Boirazian, Gloria Maria Palomo, Frauke Naumann-Winter, Enrico Costa, Darius Matusevicius, Dinah M Duarte, Eva Malikova, Dinko Vitezić, Kristina Larsson, Armando Magrelli, Violeta Stoyanova-Beninska, Segundo Mariz
Advancing rare disease treatment: EMA's decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation. Gene therapy 31 (7-8) (2024)
Enrico Costa, Antonella Isgrò, Mariane De Montalembert, Hubertus G Leufkens, Russell E Ware, Lucia De Franceschi
Successes and pitfalls in orphan drug development for sickle cell disease. Blood advances 8 (10) (2024)
Enrico Costa, Silvia Girotti, Francesca Pauro, Hubert G M Leufkens, Marco Cipolli
The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis. Orphanet journal of rare diseases 17 (1) (2022)
Enrico Costa, Prosper Tibalinda, Enrico Sterzi, Hubert M G Leufkens, Julie Makani, Eliangiringa Amos Kaale, Lucio Luzzatto
Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost. American journal of hematology 96 (1) (2020)